CAR-T CD20: Clinical trial data

An open-label, Chinese clinical trial in 7 patients with CD20-positive chemotherapy-refractory advanced DLBCL showed that CAR-T CD20 led to an overall response rate (ORR) of 75% in 4 evaluable patient...